<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00724022</url>
  </required_header>
  <id_info>
    <org_study_id>IT1850071</org_study_id>
    <secondary_id>EudraCT No. 2007-006516-31</secondary_id>
    <secondary_id>DRKS00000452</secondary_id>
    <nct_id>NCT00724022</nct_id>
  </id_info>
  <brief_title>Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation</brief_title>
  <acronym>Harmony</acronym>
  <official_title>Triple Arm, Prospectively Randomized Multi Centre Study Phase IV to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation in Non-risk Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current practice of immune suppressive standard therapy after renal transplantation in
      non-risk patients is a triple therapy consisting of steroids, a calcineurin inhibitor and
      MMF. The aim of this clinical trial is to combine a reduction of CNI using tacrolimus and a
      concept of not using steroids in order to establish an immunosuppressive regimen in
      immunologically non-risk patients that is efficient and causes as few side effects as
      possible.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this triple arm, prospectively randomized multi centre phase IV study 200 patients per
      study arm will be investigated for 12 months.

      Based on the results of the Symphony study the low dose tacrolimus study arm will be modified
      to further improve efficacy (prevention of BPAR, best possible renal function) and safety
      (adverse event profile regarding infections, cardiovascular risk factors, malignant tumours)
      of immunosuppression. For this, CNI will be reduced and in addition the rate of steroid free
      patients after 1 week will be maximized to achieve a long lasting improved post surgical
      cardiovascular risk profile (in particular concerning de novo induction of diabetes mellitus
      and other adverse events caused by steroids). Safety should be increased without loss of
      efficacy of immunosuppression (measured in rejection rate and allograft loss rate) as
      compared to an immune suppressive therapy comprising steroids. Therefore, following the
      successful study arm of the Symphony study, immunosuppression in the first of the three study
      arms comprises a steroid in combination with Advagraf and CellCept in addition to a two dose
      induction therapy with Simulect (group A). The regimen of the second study arm is similar but
      discontinues steroids on day seven after transplantation (group B). Therapy of group three is
      similar to group B but Simulect is replaced by T-cell depleting polyclonal antibodies
      (Thymoglobulin) (group C).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of immunosuppression measured in rejection rate confirmed by biopsy according to BANFF 97, modified 2005.</measure>
    <time_frame>one year after transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with steroid-free immunosuppression</measure>
    <description>Rate of patients with steroid-free immunosuppression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient and graft survival rate</measure>
    <description>patient and graft survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>graft function (calculated by the Cock- croft-Gault and MDRD-IV formula respectively calculated creatinine clearance by the Nankivell formula respectively cystatin C measurement)</measure>
    <description>graft function (calculated by the Cock- croft-Gault and MDRD-IV formula respectively calculated creatinine clearance by the Nankivell formula respectively cystatin C measurement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of steroid-resistant rejections</measure>
    <description>Number of steroid-resistant rejections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure level and also amount and types of blood pressure medications</measure>
    <description>blood pressure level and also amount and types of blood pressure medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid levels and also amount and types of lipid-lowering medications</measure>
    <description>Lipid levels and also amount and types of lipid-lowering medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight, relative weight gain [kg], BMI</measure>
    <description>body weight, relative weight gain [kg], BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infection rate, infection type and infection severity</measure>
    <description>infection rate, infection type and infection severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anemia requiring erythropoietin treatment</measure>
    <description>anemia requiring erythropoietin treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTLD incidence</measure>
    <description>PTLD incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor incidence</measure>
    <description>tumor incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of diabetes mellitus nd incidence of abnormal fasting blood sugar levels respectively incidence of impaired glucose tolerance, incidence of de novo insulin-requiring or oral-antidiabetic-requiring treatment over ≥30 days</measure>
    <time_frame>30 days</time_frame>
    <description>incidence of diabetes mellitus (ADA criteria, venous blood glucose concentration on an empty stomach ≥7.0 mmol/l, pathologic OGTT) and incidence of abnormal fasting blood sugar levels respectively incidence of impaired glucose tolerance, incidence of de novo insulin-requiring or oral-antidiabetic-requiring treatment over ≥30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of cataracts</measure>
    <description>incidence of cataracts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of avascular necrosis</measure>
    <description>incidence of avascular necrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of osteoporosis</measure>
    <description>incidence of osteoporosis (assessment of fracture rate, osteodensitometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound healing disorders</measure>
    <description>Wound healing disorders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of chronic allograft nephropathy (CAN) (12-month histology)</measure>
    <description>incidence of chronic allograft nephropathy (CAN) (12-month histology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of CMV disease (qPCR &gt;1000 copies/μL)</measure>
    <description>incidence of CMV disease (qPCR &gt;1000 copies/μL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of BKV disease (qPCR &gt;1000 copies/μL)</measure>
    <description>incidence of BKV disease (qPCR &gt;1000 copies/μL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of EBV disease (qPCR &gt;1000 copies/μL)</measure>
    <description>incidence of EBV disease (qPCR &gt;1000 copies/μL)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Disorder Related to Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard: Advagraf, CellCept, Decortin H + 2x Simulect Day 0 + 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Steroidfree: Advagraf, Cellcept, Decortin H until Day 8, 2x Simulect Day 0 + 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Steroidfree: Advagraf, Cellcept, Decortin H until Day 8, 3 x Thymoglobulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab, Tacrolimus, MMF, Prednisolon</intervention_name>
    <description>Control group. Therapy with Prednisolon.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Simulect</other_name>
    <other_name>Advagraf</other_name>
    <other_name>CellCept</other_name>
    <other_name>Decortin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab, Tacrolimus, MMF</intervention_name>
    <description>No Prednisolon after 7 days</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Simulect</other_name>
    <other_name>Advagraf</other_name>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus, MMF, rATG</intervention_name>
    <description>Induction therapy: rATG instead of Basiliximab. No Prednisolon.</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Advagraf</other_name>
    <other_name>CellCept</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post mortal kidney donation or living donation

          -  Primary and secondary renal transplantation, unless the graft was lost due to severe
             rejection within the first year

          -  PRA level ≤ 20%.

          -  Recipient ≥ 18 to 75 years of age

          -  AB0-compatible

          -  Negative crosshatch

          -  Patients with a signed informed consent form

          -  Women of child-bearing age must agree to an efficient contraception

        Exclusion Criteria:

          -  Third or multiple transplantation

          -  Transplantation per a &quot;non-heart beating&quot; donor

          -  HLA-identical living donation

          -  Incompatibility to study medication (allergy, intolerance, hypersensitivity)

          -  Patients with existing malignant underlying disease or tumour anamnesis &lt; 5 years.
             Exception: basaloma or squamous cell carcinoma of the skin after successful therapy

          -  Female patients who do not use a safe method of contraception

          -  Patients with clinically significant, uncontrolled infectious diseases (incl. HIV)
             and/or severe diarrhoea, emesis, active malabsorption of the upper gastrointestinal
             tract or active peptic ulcer

          -  Patients currently, resp. within the last 30 days, participating in other studies

          -  Primary focal-sclerosing glomerulonephritis and membranoproliferative
             glomerulonephritis as an underlying disease

          -  Autoimmune disease as underlying disease (collagen diseases, colitis, HUS, SLE) which
             might require chronic cortisone therapy

          -  Additional disease requiring temporary or chronic cortisone therapy (including
             inhalation medicine)

          -  Chronic hepatitis B and hepatitis C infection

          -  Thrombopenia &lt; 70.000/mm3 or leukopenia &lt; 2.500/mm3 or neutropenia &lt; 1500/ mm3.

          -  Patients with hepatocirrhosis Child B or C or another severe disease of the liver

          -  Patients with symptoms of a significant somatic or psychiatric / mental illness.
             Patients who are not able to realize nature, relevance and consequences of the
             clinical trial and who are not able to comply, to cooperate and communicate adequately
             and to follow the instructions of the study or even to give their informed consent
             (according to § 40 article 4 and § 41 article 2 and 3 AMG).

          -  Patients who possibly depend on the sponsor or the trial physician

          -  Patients with signs of drug abuse or alcohol abuse

          -  Patients taking additional medicines with known interactions with the immune
             suppressive substances (MMF and tacrolimus) that preclude an adequate control of the
             immunosuppression

          -  Cold ischemia time of donor kidney &gt; 30 hours

          -  Pregnant or nursing patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Hopt, Prof.Dr.Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Freiburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oliver Thomusch, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Freiburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Hugo, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaetsklinikum Erlangen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitaetsklinikum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carl Gustav Carus Universitätsklinikum</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrologisches Zentrum Niedersachsen</name>
      <address>
        <city>Hannoversch-Münden</city>
        <zip>34346</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Transplantationszentrum Kaiserslautern</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln</name>
      <address>
        <city>Koeln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln gGmbH - Krankenhaus Köln-Merheim</name>
      <address>
        <city>Koeln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum München LMU</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum der WWU Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2008</study_first_submitted>
  <study_first_submitted_qc>July 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2008</study_first_posted>
  <last_update_submitted>September 30, 2014</last_update_submitted>
  <last_update_submitted_qc>September 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Freiburg</investigator_affiliation>
    <investigator_full_name>Prof. Dr.med. Oliver Thomusch</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Kidney transplant status</keyword>
  <keyword>Steroid free</keyword>
  <keyword>Reduced</keyword>
  <keyword>Calcineurin</keyword>
  <keyword>Inhibitor</keyword>
  <keyword>Immunosuppression</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

